# Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

> **NCT04374305** · PHASE2 · RECRUITING · sponsor: **Scott R. Plotkin, MD, PhD** · enrollment: 109 (estimated)

## Conditions studied

- Neurofibromatosis Type 2
- Vestibular Schwannoma
- Non-vestibular Schwannoma
- Meningioma
- Ependymoma

## Interventions

- **DRUG:** Brigatinib
- **DRUG:** Neratinib
- **DRUG:** Retifanlimab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04374305
- **Lead sponsor:** Scott R. Plotkin, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-20
- **Primary completion:** 2029-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 109 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374305, "Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04374305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*